Guilloz Imaging Department, Central Hospital, University Hospital Center of Nancy, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France.
Université de Lorraine, Inserm, IADI, F-54000, Nancy, France.
Eur Radiol. 2021 Oct;31(10):7637-7652. doi: 10.1007/s00330-021-07745-9. Epub 2021 Mar 25.
Identify the most pertinent imaging features for solitary bone tumor characterization using a multimodality approach and propose a systematic evaluation system.
Data from a prospective trial, including 230 participants with histologically confirmed bone tumors, typical "do not touch" lesions, and stable chondral lesions, were retrospectively evaluated. Clinical data, CT, and MR imaging features were analyzed by a musculoskeletal radiologist blinded to the diagnosis using a structured report. The benign-malignant distribution of lesions bearing each image feature evaluated was compared to the benign-malignant distribution in the study sample. Benign and malignant indicators were identified. Two additional readers with different expertise levels independently evaluated the study sample.
The sample included 140 men and 90 women (mean age 40.7 ± 18.3 years). The global benign-malignant distribution was 67-33%. Seven imaging features reached the criteria for benign indicators with a mean frequency of benignancy of 94%. Six minor malignant indicators were identified with a mean frequency of malignancy of 60.5%. Finally, three major malignant indicators were identified (Lodwick-Madewell grade III, aggressive periosteal reaction, and suspected metastatic disease) with a mean frequency of malignancy of 82.4%. A bone tumor imaging reporting and data system (BTI-RADS) was proposed. The reproducibility of the BTI-RADS was considered fair (kappa = 0.67) with a mean frequency of malignancy in classes I, II, III, and IV of 0%, 2.2%, 20.1%, and 71%, respectively.
BTI-RADS is an evidence-based systematic approach to solitary bone tumor characterization with a fair reproducibility, allowing lesion stratification in classes of increasing malignancy frequency.
Clinical trial number NCT02895633 .
• The most pertinent CT and MRI criteria allowing bone tumor characterization were defined and presented. • Lodwick-Madewell grade III, aggressive periosteal reaction, and suspected metastatic disease should be considered major malignant indicators associated with a frequency of malignancy over 75%. • The proposed evidence-based multimodality reporting system stratifies solitary bone tumors in classes with increasing frequencies of malignancy.
使用多模态方法确定用于孤立性骨肿瘤特征描述的最相关成像特征,并提出一种系统评估系统。
回顾性分析了一项前瞻性试验的数据,该试验包括 230 名经组织学证实的骨肿瘤、典型的“切勿触碰”病变和稳定的软骨病变患者。由一名对诊断结果不知情的肌肉骨骼放射科医生使用结构化报告分析临床数据、CT 和 MR 成像特征。比较了评估的每种成像特征的病变的良性-恶性分布与研究样本中的良性-恶性分布。确定良性和恶性指标。另外两名具有不同专业水平的读者独立评估了研究样本。
样本包括 140 名男性和 90 名女性(平均年龄 40.7 ± 18.3 岁)。整体良性-恶性分布为 67-33%。七种成像特征达到良性指标标准,良性率平均为 94%。确定了六种较小的恶性指标,恶性率平均为 60.5%。最后,确定了三种主要的恶性指标(Lodwick-Madewell 分级 III、侵袭性骨膜反应和疑似转移性疾病),恶性率平均为 82.4%。提出了一种骨肿瘤成像报告和数据系统(BTI-RADS)。BTI-RADS 的可重复性被认为是中等的(kappa = 0.67),I、II、III 和 IV 级的恶性率分别为 0%、2.2%、20.1%和 71%。
BTI-RADS 是一种基于证据的孤立性骨肿瘤特征描述的系统方法,具有中等的可重复性,允许在恶性程度逐渐增加的类别中对病变进行分层。
临床试验编号 NCT02895633。
确定并提出了用于骨肿瘤特征描述的最相关 CT 和 MRI 标准。
Lodwick-Madewell 分级 III、侵袭性骨膜反应和疑似转移性疾病应被视为与恶性率超过 75%相关的主要恶性指标。
提出的基于证据的多模态报告系统将孤立性骨肿瘤分为恶性程度逐渐增加的类别。